Katherine Bach Kalin - Feb 2, 2023 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Role
Director
Signature
/s/ Katherine Bach Kalin
Stock symbol
SLS
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 04:10 PM
Previous filing
Aug 16, 2022
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLS Common Stock Award $0 +2.5K $0.00 2.5K Feb 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLS Stock Option (Right to Buy) Award $0 +9.5K $0.00 9.5K Feb 2, 2023 Common Stock 9.5K $3.34 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
F2 The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.